Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $16.33 Consensus Target Price from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average recommendation of "Buy" from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued a report on the stock in the last year is $16.33.

Several equities research analysts have recently commented on the stock. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Fulcrum Therapeutics in a research report on Thursday, August 1st. The Goldman Sachs Group raised shares of Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and upped their price objective for the company from $6.00 to $15.00 in a report on Monday, May 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $23.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, July 10th. Finally, Oppenheimer reduced their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an "outperform" rating for the company in a research note on Tuesday, May 14th.

Hedge Funds Weigh In On Fulcrum Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of FULC. Vestal Point Capital LP bought a new position in shares of Fulcrum Therapeutics during the fourth quarter valued at about $6,919,000. ADAR1 Capital Management LLC purchased a new position in Fulcrum Therapeutics in the 4th quarter worth approximately $4,302,000. Assenagon Asset Management S.A. purchased a new position in Fulcrum Therapeutics in the 2nd quarter worth approximately $3,084,000. Mass General Brigham Inc bought a new stake in Fulcrum Therapeutics in the first quarter valued at approximately $1,939,000. Finally, Jane Street Group LLC boosted its stake in shares of Fulcrum Therapeutics by 54.3% during the first quarter. Jane Street Group LLC now owns 535,062 shares of the company's stock valued at $5,051,000 after purchasing an additional 188,212 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock traded down $0.09 during trading on Friday, reaching $8.54. 575,774 shares of the company's stock were exchanged, compared to its average volume of 725,988. The firm's 50-day moving average price is $8.33 and its 200 day moving average price is $8.40. Fulcrum Therapeutics has a 1-year low of $3.14 and a 1-year high of $13.70. The company has a market cap of $530.80 million, a P/E ratio of -5.39 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%. The company had revenue of $80.00 million for the quarter, compared to analyst estimates of $80.00 million. During the same quarter in the previous year, the business earned ($0.38) earnings per share. As a group, equities research analysts predict that Fulcrum Therapeutics will post -0.48 EPS for the current year.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.